QFR-guided versus IVUS-guided with QFR confirmation for drug-coated balloon treatment of non-complex coronary lesions: a single-centre pilot randomised trial
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background The optimal intraprocedural decision strategy for drug-coated balloon (DCB) treatment remains unclear. This pilot randomised trial compared a quantitative flow ratio (QFR)-guided strategy, using on-line QFR and virtual PCI (vPCI), with an intravascular ultrasound (IVUS)-guided strategy with QFR confirmation (IVUS + QFR) in non-complex coronary lesions. Its aims were to assess feasibility and to estimate effect sizes for a future trial. Methods This prospective, single-centre, open-label pilot trial randomised 78 patients (82 vessels; 4 patients contributed 2 vessels each) in a 1:1 ratio to the QFR/vPCI-guided group (43 vessels) or the IVUS + QFR group (39 vessels). The primary endpoint was immediate post-procedural functional success, defined as a post-PCI QFR ≥ 0.90 assessed offline by an independent core laboratory. The primary effect measure was the absolute risk difference (RD) with a 95% confidence interval (CI) obtained by patient-level cluster bootstrap. Results All 78 randomised patients were included in the primary analysis, and primary endpoint data were available for all 82 vessels. Functional success was achieved in 79.1% (34/43) of vessels in the QFR/vPCI-guided group and 84.6% (33/39) in the IVUS + QFR group (absolute RD − 5.5 percentage points, 95% CI − 21.3 to 11.7; covariate-adjusted odds ratio 0.58, 95% CI 0.18–1.85). Stent implantation occurred in 3 vessels (7.7%), all in the IVUS + QFR group (two intraprocedural bailout procedures and one early unplanned reintervention); two of these vessels had met the QFR endpoint. A post-hoc composite of functional success without stent implantation was achieved in 79.1% and 79.5% of vessels, respectively (RD − 0.4 percentage points, 95% CI − 17.2 to 17.5). Conclusions Both strategies were feasible in DCB treatment of non-complex coronary lesions. The confidence intervals were wide, and clinically meaningful differences between the strategies cannot be excluded. A post-DCB QFR ≥ 0.90 did not exclude clinically relevant dissection. These estimates may inform the design of future confirmatory trials, which should use clinical event endpoints. Trial registration Chinese clinical trial registry ChiCTR2400084789 (registered on 24 May 2024; retrospectively registered).
Source: BMC Cardiovascular Disorders
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,090
Award: G3624248983
OpenAlex ID: W7207865530
